ArticleFrontiers in oncology2026

Development and validation of a pathomics-driven machine learning model for individualized prediction of neoadjuvant chemotherapy response and early recurrence in HR-positive, HER2-negative breast cancer.

Jiaxian Yue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.